Jul 11, 2020

By providing laboratories with two serological antibody tests (IgG and Total including IgG, IgA and IgM), intended for the detection of the immune response associated with the new coronavirus, Ortho offers a complete and precise solution responding to the current challenges of the pandemic. VITROS® anti-SARS-CoV-2 tests automated on Ortho's high-speed VITROS® platforms have demonstrated 100% specificity in test validation studies and validated by the National Reference Center (CNR) in France.


It is only with a specificity of 100% that one can be completely sure that the result of the positive antibody test is really positive.


These two CE marked IgG and Total antibody tests evaluated by the CNR bring real progress for the management of the COVID-19 epidemic due to their precision, 100% sensitivity from 8 days post symptoms and their excellent positive predictive value linked in particular to targeting of the most specific protein S1 to the SARS-CoV-2 virus. The value of the signal obtained increases as the amount of anti-SARS-CoV-2 antibody in the sample increases.


Read the Press release in French here:


Ortho Clinical Diagnostics lance deux tests sérologiques pour la détection des anticorps anti-SARS-CoV-2 avec une spécificité de 100% (PDF)

Press contact:

For media inquiries please contact

Ortho Media Relations
Ortho Clinical Diagnostics